Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Child Abuse & Neglect|May 30, 2009
Screening for harsh punishment in a pediatric primary care clinicSusan Feigelman, Howard Dubowitz, Wendy Lane, et al.
Diabetes, Obesity & Metabolism|January 7, 2020
The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mLAthena Philis-Tsimikas, Wendy Lane, Ulrik Pedersen-Bjergaard, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 12, 2021
Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database StudyWendy Lane, Mads Faurby, Lise Lotte N Husemoen, et al.
Pediatrics|March 3, 2007
Screening for depression in an urban pediatric primary care clinicHoward Dubowitz, Susan Feigelman, Wendy Lane, et al.
PLOS Global Public Health|February 2, 2024
Prevalence, trends, and factors associated with maternal autonomy regarding healthcare, finances, and mobility in Bangladesh: Analysis of Demographic and Health Surveys 1999-2018Gulam Muhammed Al Kibria, Jennifer Albrecht, Wendy Lane, et al.
Diabetes Technology & Therapeutics|July 8, 2020
Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID StudyThomas Blevins, Wendy Lane, David Rodbard, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 15, 2022
Effective Overall Glycaemic Control with Fast-Acting Insulin Aspart Across Patients with Different Baseline Characteristics: A Post Hoc Analysis of the Onset 9 TrialWendy Lane, Elena Favaro, Esteban Jódar, et al.
Mayo Clinic Proceedings|December 15, 2004
Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trialRobert Tanenberg, Bruce Bode, Wendy Lane, et al.
Lancet (London, England)|May 8, 2023
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trialChantal Mathieu, Björg Ásbjörnsdóttir, Harpreet S Bajaj, et al.
JAMA|July 4, 2017
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical TrialWendy Lane, Timothy S Bailey, Gregg Gerety, et al.
Pageof 3